0.3919
price down icon8.84%   -0.038
pre-market  プレマーケット:  .39   -0.0019   -0.48%
loading
前日終値:
$0.4299
開ける:
$0.4168
24時間の取引高:
5.51M
Relative Volume:
0.90
時価総額:
$145.66M
収益:
$52.29M
当期純損益:
$-134.84M
株価収益率:
-0.5225
EPS:
-0.75
ネットキャッシュフロー:
$-117.11M
1週間 パフォーマンス:
-17.06%
1か月 パフォーマンス:
+0.49%
6か月 パフォーマンス:
-26.61%
1年 パフォーマンス:
-57.43%
1日の値動き範囲:
Value
$0.38
$0.4222
1週間の範囲:
Value
$0.38
$0.55
52週間の値動き範囲:
Value
$0.345
$1.06

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name
名前
Sangamo Therapeutics Inc
Name
セクター
Healthcare (1108)
Name
電話
(510) 970-6000
Name
住所
501 CANAL BLVD., RICHMOND, CA
Name
職員
183
Name
Twitter
@sangamotx
Name
次回の収益日
2025-05-02
Name
最新のSEC提出書
Name
SGMO's Discussions on Twitter

Compare SGMO vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SGMO
Sangamo Therapeutics Inc
0.3919 159.79M 52.29M -134.84M -117.11M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.27 123.47B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
766.66 83.60B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
748.72 46.83B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.65 43.11B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
297.04 34.79B 5.36B 287.73M 924.18M 2.5229

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-11-07 ダウングレード Barclays Overweight → Equal Weight
2024-12-13 アップグレード Truist Hold → Buy
2024-12-10 繰り返されました H.C. Wainwright Buy
2023-11-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2023-04-28 ダウングレード BofA Securities Neutral → Underperform
2023-02-27 アップグレード Wedbush Neutral → Outperform
2023-01-06 ダウングレード BofA Securities Buy → Neutral
2022-06-13 再開されました Wedbush Neutral
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-01-07 再開されました Guggenheim Neutral
2021-01-06 開始されました Stifel Hold
2020-12-16 再開されました H.C. Wainwright Buy
2020-09-08 開始されました BofA Securities Buy
2020-07-07 開始されました SunTrust Buy
2019-08-26 開始されました H.C. Wainwright Buy
2018-11-14 ダウングレード JP Morgan Overweight → Neutral
2018-11-09 ダウングレード Guggenheim Buy → Neutral
2018-10-10 開始されました Guggenheim Buy
2018-06-20 開始されました BofA/Merrill Buy
2017-11-15 アップグレード Piper Jaffray Neutral → Overweight
2017-06-22 再開されました Jefferies Buy
2016-11-01 ダウングレード Wedbush Outperform → Neutral
2016-10-19 ダウングレード Piper Jaffray Overweight → Neutral
2015-12-04 開始されました Wells Fargo Outperform
2015-10-23 再開されました Jefferies Buy
2013-05-03 開始されました BioLogic Equity Research Sell
2011-02-23 繰り返されました JMP Securities Mkt Outperform
2010-07-29 繰り返されました Wedbush Outperform
2009-10-19 開始されました Brean Murray Sell
2009-10-07 繰り返されました Leerink Swann Outperform
2009-08-25 繰り返されました JMP Securities Mkt Outperform
すべてを表示

Sangamo Therapeutics Inc (SGMO) 最新ニュース

pulisher
Mar 03, 2026

Risk Report: Does Sangamo Therapeutics Inc have consistent dividend growth - baoquankhu1.vn

Mar 03, 2026
pulisher
Mar 02, 2026

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

Merger Talk: Does Sangamo Therapeutics Inc have consistent dividend growth2025 Buyback Activity & Technical Pattern Based Buy Signals - baoquankhu1.vn

Mar 02, 2026
pulisher
Mar 01, 2026

SGMO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 01, 2026
pulisher
Feb 26, 2026

Sangamo (NASDAQ: SGMO) CEO surrenders shares for RSU tax withholding - Stock Titan

Feb 26, 2026
pulisher
Feb 26, 2026

Sangamo (NASDAQ: SGMO) SVP surrenders shares to cover RSU tax withholding - Stock Titan

Feb 26, 2026
pulisher
Feb 26, 2026

EDGAR Filing Documents for 0001628280-24-042308 - SEC.gov

Feb 26, 2026
pulisher
Feb 24, 2026

symbol__ Stock Quote Price and Forecast - CNN

Feb 24, 2026
pulisher
Feb 22, 2026

SGMO Should I Buy - Intellectia AI

Feb 22, 2026
pulisher
Feb 18, 2026

Retail Trends: Is Sangamo Therapeutics Inc a strong growth stock2025 Volatility Report & Capital Protection Trading Alerts - baoquankhu1.vn

Feb 18, 2026
pulisher
Feb 16, 2026

Sangamo Therapeutics (SGMO) price target increased by 17.31% to 3.89 - MSN

Feb 16, 2026
pulisher
Feb 13, 2026

How liquid is Sangamo Therapeutics Inc. stockExit Point & Smart Investment Allocation Tips - mfd.ru

Feb 13, 2026
pulisher
Feb 13, 2026

Is Sangamo Therapeutics Inc. stock a hidden gem2025 Trading Recap & Consistent Profit Focused Trading Strategies - mfd.ru

Feb 13, 2026
pulisher
Feb 11, 2026

Is Sangamo Therapeutics Inc. benefiting from innovation trendsWeekly Investment Report & Expert Verified Movement Alerts - mfd.ru

Feb 11, 2026
pulisher
Feb 11, 2026

FY2030 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat

Feb 11, 2026
pulisher
Feb 10, 2026

Sangamo Therapeutics' (SGMO) Buy Rating Reiterated at HC Wainwright - MarketBeat

Feb 10, 2026
pulisher
Feb 10, 2026

SGMO: HC Wainwright & Co. Maintains Buy Rating with $10 PT | SGM - GuruFocus

Feb 10, 2026
pulisher
Feb 05, 2026

Assessing Sangamo Therapeutics (SGMO) Valuation After New Fabry Data Financing Move And Leadership Changes - simplywall.st

Feb 05, 2026
pulisher
Feb 05, 2026

Sangamo starts FDA submission seeking approval of Fabry gene therapy - Fabry Disease News

Feb 05, 2026
pulisher
Feb 04, 2026

Sangamo prices $25 million offering of common stock and warrants By Investing.com - Investing.com Nigeria

Feb 04, 2026
pulisher
Feb 04, 2026

What Sangamo Therapeutics (SGMO)'s Fabry Gene Therapy Progress And Equity Raise Means For Shareholders - Sahm

Feb 04, 2026
pulisher
Feb 04, 2026

Sangamo Biosciences launches dilutive February 2026 financing - TipRanks

Feb 04, 2026
pulisher
Feb 04, 2026

Sangamo Therapeutics Signs Multiple Material Agreements - TradingView

Feb 04, 2026
pulisher
Feb 04, 2026

Form 424B5 SANGAMO THERAPEUTICS, - StreetInsider

Feb 04, 2026
pulisher
Feb 04, 2026

Sangamo To Present Positive Study Data Of ST-920 In Fabry Disease At WORLD Symposium 2026 - Nasdaq

Feb 04, 2026
pulisher
Feb 04, 2026

Should FDA Accelerated Approval Pathway for ST-920 Gene Therapy Data Require Action From Sangamo Therapeutics (SGMO) Investors? - Yahoo Finance

Feb 04, 2026
pulisher
Feb 04, 2026

Sangamo (SGMO) Appoints Interim CFO Amid Leadership Change - GuruFocus

Feb 04, 2026
pulisher
Feb 03, 2026

Sangamo Therapeutics (SGMO) Price Target Increased by 17.31% to 3.89 - Nasdaq

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo gene therapy shows positive kidney function results in Fabry disease - Investing.com India

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 - The Manila Times

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo gene therapy shows positive kidney function results in Fabry disease By Investing.com - Investing.com South Africa

Feb 03, 2026
pulisher
Feb 03, 2026

One-time Fabry gene therapy lifts kidney function in early trial data - Stock Titan

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo Shares Fall After Pricing $25 Million Public Offering - marketscreener.com

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo Therapeutics (SGMO) Stock Plummets 28% After $25M Offeri - GuruFocus

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo stock plunges after pricing $25 million dilutive offering By Investing.com - Investing.com India

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo Prices $250 Mln Offering; Stock Plunges - Nasdaq

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo stock plunges after pricing $25 million dilutive offering - Investing.com

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo plunges after pricing stock offering; principal financial officer exits - Seeking Alpha

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo Therapeutics reports preliminary cash balance and CFO transition By Investing.com - Investing.com Australia

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo Therapeutics reports preliminary cash balance and CFO transition - Investing.com Nigeria

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo Therapeutics to Raise $25 Million Through Public Offering of Common Stock - geneonline.com

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo Therapeutics IncOn Feb 2, Prathyusha Duraibabu terminated as principal financial officerSEC filing - marketscreener.com

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo (SGMO) Appoints Nikunj Jain as Interim CFO - GuruFocus

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo (SGMO) Announces New Stock Offering to Raise $25M - GuruFocus

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo (SGMO) Reports Estimated Year-End Cash Holdings - GuruFocus

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo Therapeutics slides after $25 million stock sale - TradingView

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo Therapeutics Prices Underwritten Offering of Common Stock and Warrants, Expected to Raise Approximately $25 Million - Quiver Quantitative

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo prices $25 million offering of common stock and warrants - Investing.com

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering - The Manila Times

Feb 03, 2026
pulisher
Feb 03, 2026

Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Stock's 29% Jump Looks Justified - 富途牛牛

Feb 03, 2026
pulisher
Feb 03, 2026

Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Boosted 29% But Its Business Prospects Need A Lift Too - simplywall.st

Feb 03, 2026

Sangamo Therapeutics Inc (SGMO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$49.83
price down icon 5.71%
$27.85
price down icon 0.89%
$47.48
price up icon 0.02%
$100.76
price down icon 6.25%
$147.00
price up icon 0.46%
biotechnology ONC
$297.04
price down icon 5.51%
大文字化:     |  ボリューム (24 時間):